AXIM AXIM BIOTECHNOLOGIES, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1514946 · Fiscal year ends 12/31
Financial factors as of 2022-09-30 (2022Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-89.0%
TTM net income YoY-29.0%
TTM EPS YoY282.5%
Revenue 3-yr CAGR-67.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-182,235.4%
Net margin-218,733.8%
FCF margin—
EBITDA margin-142,796.3%
Returns
ROE-10,021.6%
ROA-143.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets197.8%
Debt / equity—
Current ratio0.08x
Interest coverage-7.07x
Cash quality & payout
Operating cash flow / net income0.19x
Accruals ratio-116.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 | FY20192019-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $39,518 | $8,875 | $60,460 | $0 | $799,483 |
| Cost of revenue | — | — | — | $0 | $0 |
| Gross profit | — | — | — | $0 | $0 |
| R&D expense | $125,496 | $153,697 | $284,869 | $426,708 | $0 |
| SG&A expense | $2.24M | $4.08M | $5.67M | $4.51M | $3.11M |
| Operating income | -$2.75M | -$4.65M | -$13.97M | -$4.95M | -$3.11M |
| Interest expense | $140,000 | $261,537 | $140,389 | $234,754 | $222,236 |
| Pretax income | -$8.06M | -$6.24M | -$16.02M | -$6.29M | -$2.97M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.06M | -$6.24M | -$16.03M | -$6.41M | -$6.45M |
| EBITDA | -$2.32M | -$4.23M | -$11.86M | -$4.93M | -$3.11M |
| EPS (basic) | -0.04 | -0.04 | 0.12 | -0.06 | -0.10 |
| EPS (diluted) | -0.04 | -0.04 | 0.12 | -0.06 | -0.10 |
| Weighted avg. shares (diluted) | — | — | — | 110.39M | 61.95M |
| Banking | |||||
| Noninterest expense | $0 | $177,500 | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $156,457 | $47,282 | $452,963 | $457,181 | $511,630 |
| Receivables | — | — | — | $0 | $315,843 |
| Inventory | — | — | $20,089 | $0 | $487,814 |
| Current assets | $156,457 | $103,979 | $636,613 | $713,104 | $1.64M |
| PP&E, net | $134,067 | $93,840 | $116,810 | $104,094 | $2,237 |
| Goodwill | — | — | $0 | $2.46M | $0 |
| Intangibles | — | $3.99M | — | — | $50,534 |
| Total assets | $4.12M | $4.21M | $5.32M | $11.31M | $1.69M |
| Current liabilities | $5.98M | $3.39M | $2.58M | $1.50M | $3.40M |
| Short-term debt | $94,829 | $19,789 | $180 | $180 | $5,000 |
| Long-term debt | $137,044 | — | — | — | — |
| Total debt | $231,873 | — | — | — | — |
| Total liabilities | $11.78M | $9.04M | $7.66M | $9.75M | $8.45M |
| Shareholders' equity | -$7.66M | -$4.83M | -$2.34M | $1.57M | -$6.76M |
| Net debt | $75,416 | — | — | — | — |
| Shares outstanding | 245.93M | 192.44M | 138.10M | 125.33M | 64.85M |
| Cash flow statement | |||||
| Operating cash flow | -$1.03M | -$2.04M | -$2.49M | -$3.22M | -$5.04M |
| Capital expenditure | $0 | $8,710 | $40,495 | $97,324 | — |
| Free cash flow | -$1.03M | -$2.05M | -$2.53M | -$3.31M | — |
| Investing cash flow | $0 | -$8,710 | -$50,495 | $9,980 | $348,187 |
| Financing cash flow | $1.14M | $1.65M | $2.53M | $3.15M | $3.40M |
| Depreciation & amortization | $427,019 | $426,126 | $2.12M | $16,001 | $3,356 |
| Stock-based compensation | $197,727 | $1.11M | $1.14M | $2.31M | $1.83M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.